Components of heart rate variability have attracted considerable attention in psychology and medicine and have become important dependent measures in psychophysiology and behavioral medicine. Quantification and interpretation of heart rate variability, however, remain complex issues and are fraught with pitfalls. The present report (a) examines the physiological origins and mechanisms of heart rate variability, (b) considers quantitative approaches to measurement, and (c) highlights important caveats in the interpretation of heart rate variability. Summary guidelines for research in this area are outlined, and suggestions and prospects for future developments are considered.

No abstract

Abstract-Depression is commonly present in patients with coronary heart disease (CHD) and is independently associated with increased cardiovascular morbidity and mortality. Screening tests for depressive symptoms should be applied to identify patients who may require further assessment and treatment. This multispecialty consensus document reviews the evidence linking depression with CHD and provides recommendations for healthcare providers for the assessment, referral, and treatment of depression. (Circulation. 2008;118:1768-1775.)

Writing Committee for the ENRICHD Investigators C ARDIOVASCULAR DISEASE IS THE leading cause of death and a major cause of morbidity and disability in the United States, with an estimated 6 million people having symptomatic coronary heart disease (CHD). 1 Recent studies 2-7 have shown that depression and low perceived social support (LPSS) are associated with increased cardiac morbidity and mortality in CHD patients. In patients with CHD, the prevalence of major depression is nearly 20% and the prevalence of minor depression is approximately 27%. 8-10 After an acute myocardial infarction (MI), depression is a risk factor for mortality independent of cardiac disease severity. 4,6 A recent randomized clinical trial found that the antidepressant sertraline hydrochloride was effective in treating recurrent depression in patients with either an acute MI or an episode of unstable angina. 11 However, no clinical trial has examined whether treating depression with counseling or antidepressants after an acute MI improves survival or reduces cardiac risk. The absence of social support is also a risk factor for cardiac morbidity and mortality in patients with CHD. 2,3,5,7 No clinical trial has tested the effects of increasing social support on clinical end points following acute MI, although

The goal of evidence-based medicine is ultimately to improve patient outcomes and quality of care. Systematic reviews of the available published evidence are required to identify interventions that lead to improvements in behavior, health, and well-being. Authoritative literature reviews depend on the quality of published research and research reports. The Consolidated Standards for Reporting Trials (CONSORT) Statement (www.consort-statement.org) was developed to improve the design and reporting of interventions involving randomized clinical trials (RCTs) in medical journals. We describe the 22 CONSORT guidelines and explain their application to behavioral medicine research and to evidence-based practice. Additional behavioral medicine-specific guidelines (e.g., treatment adherence) are also presented. Use of these guidelines by clinicians, educators, policymakers, and researchers who design, report, and evaluate or review RCTs will strengthen the research itself and accelerate efforts to apply behavioral medicine research to improve the processes and outcomes of behavioral medicine practice.